GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » EV-to-Revenue

Fusen Pharmaceutical Co (HKSE:01652) EV-to-Revenue : 1.98 (As of May. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Fusen Pharmaceutical Co's enterprise value is HK$1,226.9 Mil. Fusen Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$618.7 Mil. Therefore, Fusen Pharmaceutical Co's EV-to-Revenue for today is 1.98.

The historical rank and industry rank for Fusen Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

HKSE:01652' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.16   Med: 3.12   Max: 11.43
Current: 1.98

During the past 9 years, the highest EV-to-Revenue of Fusen Pharmaceutical Co was 11.43. The lowest was 1.16. And the median was 3.12.

HKSE:01652's EV-to-Revenue is ranked better than
57.32% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs HKSE:01652: 1.98

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-27), Fusen Pharmaceutical Co's stock price is HK$1.20. Fusen Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.82. Therefore, Fusen Pharmaceutical Co's PS Ratio for today is 1.46.


Fusen Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Fusen Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co EV-to-Revenue Chart

Fusen Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 8.19 5.81 2.43 2.18 2.19

Fusen Pharmaceutical Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.43 - 2.18 - 2.19

Competitive Comparison of Fusen Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Fusen Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusen Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fusen Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fusen Pharmaceutical Co's EV-to-Revenue falls into.



Fusen Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Fusen Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1226.932/618.65
=1.98

Fusen Pharmaceutical Co's current Enterprise Value is HK$1,226.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusen Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$618.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusen Pharmaceutical Co  (HKSE:01652) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Fusen Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.20/0.822
=1.46

Fusen Pharmaceutical Co's share price for today is HK$1.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusen Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusen Pharmaceutical Co (HKSE:01652) Business Description

Traded in Other Exchanges
N/A
Address
Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN
Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.
Executives
Cao Changcheng 2201 Interest of corporation controlled by you
Quan Xiufeng 2202 Interest of your spouse
Full Bliss Holdings Limited 2101 Beneficial owner
One Victory Investments Limited 2101 Beneficial owner
Cao Zhiming 2201 Interest of corporation controlled by you
Zhou Peilin 2202 Interest of your spouse
Rayford Global Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
First Joint Elegant Limited 2101 Beneficial owner
Fung Wai Sze 2202 Interest of your spouse
Lam Yiu Por 2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines